Price
No data yet.
Social Signal Score
Analyst Ratings
2 analystsRevenue
$102.9KAnalyst Estimates
Consensus estimates, not results. Via Financial Modeling Prep.
Company Profile
- CEO
- David Allan White
- Sector
- Healthcare
- Industry
- Biotechnology
- Employees
- 2
- Beta
- 2.61
- Country
- US
- Piotroski score
- 3 / 9 (Weak)
- Altman Z-score
- -21.97
Financials
Revenue
$102.9K+76.0%Net Income
$-31.63MEBITDA
$-31.62MFree Cash Flow
$-1.72MEPS (diluted)
$-76.01Shares Outstanding (diluted)
416.1K+126379.3%Operating Expenses
$1.48MCash & Debt
$2.74MReturn of Capital
$0.00Revenue by Segment (annual)
$0.60Quote
Valuation & Ratios
Returns & Efficiency
Revenue & Net Income (Annual)
| Fiscal Year | Revenue | Net Income | EPS |
|---|---|---|---|
| 2025 | $815.4K | $-14.03M | $-47.30 |
| 2024 | $2.52M | $-58.69M | $-5209.29 |
| 2023 | $58.5K | $-37.41M | $-250.29 |
| 2022 | $0.00 | $-13.42M | $-1.10 |
| 2021 | $0.00 | $-3.42M | $-0.89 |
| 2020 | $0.00 | $-1.60M | $-0.40 |
| 2019 | $0.00 | $-821.9K | $-0.21 |
Valuation
ONCOhas no positive reported earnings per share, so an earnings-multiple projection can't be built for it. Companies are valued on other measures at this stage — revenue growth, cash burn, or book value — none of which this calculator models.
Signal Score (90d)
30+0.00%Social Signal Score
Mentions (9)
- Newsglobenewswire.com·26d ago·Negative
Onconetix Acquisition Target Realbotix Launches Echo Humanoid Robot Line with Tabletop and Full Body Models Designed for Education, Wellness, and Social Engagement Echo Tabletop Priced at $11,950 and Echo Full Body at $59,950; First Production Run of 250 Units Available for 2027 Delivery; Onconetix Recently Entered into a Definitive Agreement to Acquire Realbotix LLC, a Subsidiary of Realbotix Corp.
View source ↗ - Newsglobenewswire.com·27d ago·Neutral
Onconetix Announces Reverse Stock Split CINCINNATI, Ohio, Oct. 26, 2026 (GLOBE NEWSWIRE) -- Onconetix, Inc. (Nasdaq: ONCO) (the “Company”), today announced that its Board of Directors has approved a one-for-ten (1-for-10) reverse stock split of the Company's outstanding common stock. The reverse split is expected to become effective at 12:01 a.m. Eastern Time on November 6, 2026. The Company's common stock has been assigned a new CUSIP number, 68237Q500, in connection with the reverse stock spli…
View source ↗ - Newsglobenewswire.com·30d ago·Negative
…ility Automatically Cancelled and Discharged in Full Upon Closing of Pending Acquisition CINCINNATI, Ohio, Oct. 23, 2026 (GLOBE NEWSWIRE) -- Onconetix, Inc. (Nasdaq: ONCO) (“Onconetix” or the “Company”) today announced that it has made an additional advance of $500,000 to Realbotix LLC (“Realbotix”), the target of its previously announced pending acquisition, under the strategic bridge financing facility (the “Grid Note”) announced on September 14, 2026. The additional advance brings the total p…
View source ↗ - Newsbusinesswire.com·30d ago·Negative
Realbotix Announces Additional Draw under Bridge Loan from Onconetix LAS VEGAS--(BUSINESS WIRE)--Realbotix Corp. (TSX-V: XBOT) (Frankfurt: 76M0.F) (OTC: XBOTF) (“Realbotix” or the “Company”), a leader in humanoid robotics and embodied AI, announces that its wholly owned subsidiary, Realbotix LLC, has agreed to an additional advance of US$500,000 in connection with the loan agreement entered into with Onconetix, Inc. (“Onconetix”) on September 14, 2026 in connection with the proposed merger trans
View source ↗ - Newsglobenewswire.com·59d ago·Positive
SRX Global Provides Shareholders with Update on Liquidation of Two Portfolio Investments and Adds an Investment in Onconetix (Nasdaq: ONCO) SRX has added ONCO in anticipation of Realbotix LLC acquisition closing. Believes Vinci AI Vision system is extremely undervalued and misunderstood, with multiple potential applications in defense, ranging from drones for facial recognition to body cameras. SRX has added ONCO in anticipation of Realbotix LLC acquisition closing. Believes Vinci AI Vision syst…
View source ↗ - Newsglobenewswire.com·69d ago·Negative
CORRECTED: Onconetix Provides Strategic Bridge Financing to Realbotix LLC in Support of Pending Acquisition Initial Advance of $2.5 Million to Realbotix LLC to Support Growth and Working Capital; Non-Interest Bearing Facility Is Automatically Cancelled and Discharged in Full Upon Closing of Pending Acquisition
View source ↗ - Newsglobenewswire.com·69d ago·Negative
Onconetix Provides Strategic Bridge Financing to Realbotix LLC in Support of Pending Acquisition Initial Advance of $2.5 Million to Realbotix LLC to Support Growth and Working Capital; Non-Interest Bearing Facility Is Automatically Cancelled and Discharged in Full Upon Closing of Pending Acquisition
View source ↗ - Newsbusinesswire.com·69d ago·Negative
Realbotix LLC Announces Bridge Loan from Onconetix LAS VEGAS--(BUSINESS WIRE)--Realbotix Corp. (TSX-V: XBOT) (Frankfurt: 76M0.F) (OTC: XBOTF) (“Realbotix” or the “Company”), a leader in humanoid robotics and embodied AI, announces that its wholly owned subsidiary, Realbotix LLC, has entered into a loan agreement with Onconetix, Inc. (“Onconetix”) for an unsecured bridge loan facility in connection with the proposed merger transaction involving Realbotix LLC and Onconetix previously announced on
View source ↗ - Newsglobenewswire.com·80d ago·Negative
Onconetix Acquisition Target Realbotix Launches Pilot with Leading European Telecommunications Company to Deploy Humanoid Robots in Live Presentations and Events Pilot Tests Humanoid Robots as Presenters, Hosts, and Brand Ambassadors Before Live Audiences, Extending Robot Capabilities Beyond One-on-One Interaction into Dynamic, Audience-Facing Environments; Onconetix Entered into a Definitive Agreement to Acquire Realbotix LLC, a Subsidiary of Realbotix Corp.
View source ↗
Earnings
Thu, Mar 11(in 4 months)
Consensus estimate $-450500.00 per share
Typical surprise +99.4% (median, so one quarter with a near-zero estimate can't distort it)
- Mon, Nov 16$-2.97 vs $-45050.00beat
- Thu, Aug 13$-12.80 vs $-4505.00beat
- Fri, Mar 13$10.40 vs $-35700.00beat
- Thu, Nov 13$-312.50 vs $-32300.00beat
- Thu, Aug 14$-202.50 vs $-20400.00beat
- Thu, Jun 12$-1059.32 vs $-34850.00beat
Estimates and results for ONCO via Financial Modeling Prep. Beating consensus says the company cleared the bar analysts set, not that the business grew.
Insider trading
Open-market buys and sells by ONCO officers and directors.
- Bought
- $153k
- Sold
- $144k
3 trades
3 trades
- Hrt Financial Lpsold
- Hrt Financial Lpsold
- Hrt Financial Lpbought
- Hrt Financial Lpsold
- Hrt Financial Lpbought
- Hrt Financial Lpbought
35 further Form 4 entries are share awards, option exercises or shares withheld for tax. Those are compensation, not trades, so they are excluded above. Buying is the stronger signal: an insider spends their own money for one reason. Selling has many innocent explanations — tax, diversifying, a house — so it says far less than it appears to. Via SEC filings.
Congress trades
No disclosed congressional trades in ONCO.
Self-reported filings, amounts as brackets. Via Senate/House disclosures.
